Følg
Matthew Hassler
Matthew Hassler
Umass Medical School
Verifisert e-postadresse på mail.mcgill.ca
Tittel
Sitert av
Sitert av
År
Exosome-mediated delivery of hydrophobically modified siRNA for huntingtin mRNA silencing
MC Didiot, LM Hall, AH Coles, RA Haraszti, BMDC Godinho, K Chase, ...
Molecular Therapy 24 (10), 1836-1847, 2016
4992016
A divalent siRNA chemical scaffold for potent and sustained modulation of gene expression throughout the central nervous system
JF Alterman, BMDC Godinho, MR Hassler, CM Ferguson, D Echeverria, ...
Nature biotechnology 37 (8), 884-894, 2019
2022019
RNAi modulation of placental sFLT1 for the treatment of preeclampsia
AA Turanov, A Lo, MR Hassler, A Makris, A Ashar-Patel, JF Alterman, ...
Nature biotechnology 36 (12), 1164-1173, 2018
1842018
Diverse lipid conjugates for functional extra-hepatic siRNA delivery in vivo
A Biscans, A Coles, R Haraszti, D Echeverria, M Hassler, M Osborn, ...
Nucleic acids research 47 (3), 1082-1096, 2019
1802019
Comparison of partially and fully chemically-modified siRNA in conjugate-mediated delivery in vivo
MR Hassler, AA Turanov, JF Alterman, RA Haraszti, AH Coles, MF Osborn, ...
Nucleic acids research 46 (5), 2185-2196, 2018
1792018
Hydrophobically modified siRNAs silence huntingtin mRNA in primary neurons and mouse brain
JF Alterman, LM Hall, AH Coles, MR Hassler, MC Didiot, K Chase, ...
Molecular therapy Nucleic acids 4, 2015
1712015
Hydrophobicity drives the systemic distribution of lipid-conjugated siRNAs via lipid transport pathways
MF Osborn, AH Coles, A Biscans, RA Haraszti, L Roux, S Davis, S Ly, ...
Nucleic acids research 47 (3), 1070-1081, 2019
1332019
Heavily and fully modified RNAs guide efficient SpyCas9-mediated genome editing
A Mir, JF Alterman, MR Hassler, AJ Debacker, E Hudgens, D Echeverria, ...
Nature Communications 9 (1), 2641, 2018
1172018
Docosahexaenoic acid conjugation enhances distribution and safety of siRNA upon local administration in mouse brain
M Nikan, MF Osborn, AH Coles, BMDC Godinho, LM Hall, RA Haraszti, ...
Molecular therapy Nucleic acids 5, 2016
1022016
Optimized cholesterol-siRNA chemistry improves productive loading onto extracellular vesicles
RA Haraszti, R Miller, MC Didiot, A Biscans, JF Alterman, MR Hassler, ...
Molecular Therapy 26 (8), 1973-1982, 2018
982018
Serum deprivation of mesenchymal stem cells improves exosome activity and alters lipid and protein composition
RA Haraszti, R Miller, ML Dubuke, HE Rockwell, AH Coles, E Sapp, ...
Iscience 16, 230-241, 2019
812019
Fully stabilized asymmetric sirna
A Khvorova, N Aronin, M Hassler, J Alterman
US Patent App. 15/089,423, 2016
772016
Androgen-regulated expression of arginase 1, arginase 2 and interleukin-8 in human prostate cancer
PO Gannon, J Godin-Ethier, M Hassler, N Delvoye, M Aversa, AO Poisson, ...
PloS one 5 (8), e12107, 2010
762010
Bis-diimidazolylidine complexes of nickel: Investigations into nickel catalyzed coupling reactions
TAP Paulose, SC Wu, JA Olson, T Chau, N Theaker, M Hassler, JW Quail, ...
Dalton Transactions 41 (1), 251-260, 2012
612012
Pharmacokinetic profiling of conjugated therapeutic oligonucleotides: a high-throughput method based upon serial blood microsampling coupled to peptide nucleic acid …
BMDC Godinho, JW Gilbert, RA Haraszti, AH Coles, A Biscans, L Roux, ...
nucleic acid therapeutics 27 (6), 323-334, 2017
522017
Guanabenz (Wytensin™) selectively enhances uptake and efficacy of hydrophobically modified siRNAs
MF Osborn, JF Alterman, M Nikan, H Cao, MC Didiot, MR Hassler, ...
Nucleic acids research 43 (18), 8664-8672, 2015
522015
Novel cluster and monomer-based GalNAc structures induce effective uptake of siRNAs in vitro and in vivo
VK Sharma, MF Osborn, MR Hassler, D Echeverria, S Ly, EA Ulashchik, ...
Bioconjugate chemistry 29 (7), 2478-2488, 2018
452018
Cell type impacts accessibility of mRNA to silencing by RNA interference
CM Ferguson, D Echeverria, M Hassler, S Ly, A Khvorova
Molecular Therapy Nucleic Acids 21, 384-393, 2020
382020
Chemical engineering of therapeutic siRNAs for allele-specific gene silencing in Huntington’s disease models
F Conroy, R Miller, JF Alterman, MR Hassler, D Echeverria, ...
Nature communications 13 (1), 5802, 2022
322022
An RNAi therapeutic targeting hepatic DGAT2 in a genetically obese mouse model of nonalcoholic steatohepatitis
B Yenilmez, N Wetoska, M Kelly, D Echeverria, K Min, L Lifshitz, ...
Molecular Therapy 30 (3), 1329-1342, 2022
322022
Systemet kan ikke utføre handlingen. Prøv på nytt senere.
Artikler 1–20